The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation
- 1 July 2004
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (7) , 1144-1153
- https://doi.org/10.1359/jbmr.040302
Abstract
Chloride channel activity is essential for osteoclast function. Consequently, inhibition of the osteoclastic chloride channel should prevent bone resorption. Accordingly, we tested a chloride channel inhibitor on bone turnover and found that it inhibits bone resorption without affecting bone formation. This study indicates that chloride channel inhibitors are highly promising for treatment of osteoporosis. Introduction: The chloride channel inhibitor, NS3736, blocked osteoclastic acidification and resorption in vitro with an IC50 value of 30 μM. When tested in the rat ovariectomy model for osteoporosis, daily treatment with 30 mg/kg orally protected bone strength and BMD by ∼50% 6 weeks after surgery. Most interestingly, bone formation assessed by osteocalcin, mineral apposition rate, and mineralized surface index was not inhibited. Materials and Methods: Analysis of chloride channels in human osteoclasts revealed that ClC-7 and CLIC1 were highly expressed. Furthermore, by electrophysiology, we detected a volume-activated anion channel on human osteoclasts. Screening 50 different human tissues showed a broad expression for CLIC1 and a restricted immunoreactivity for ClC-7, appearing mainly in osteoclasts, ovaries, appendix, and Purkinje cells. This highly selective distribution predicts that inhibition of ClC-7 should specifically target osteoclasts in vivo. We suggest that NS3736 is inhibiting ClC-7, leading to a bone-specific effect in vivo. Results and Conclusion: In conclusion, we show for the first time that chloride channel inhibitors can be used for prevention of ovariectomy-induced bone loss without impeding bone formation. We speculate that the coupling of bone resorption to bone formation is linked to the acidification of the resorption lacunae, thereby enabling compounds that directly interfere with this process to be able to positive uncouple this process resulting in a net bone gain.Keywords
This publication has 31 references indexed in Scilit:
- Transforming Growth Factor-β Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK ExpressionJournal of Biological Chemistry, 2003
- Mapping of Autosomal Dominant Osteopetrosis Type II (Albers-Schönberg Disease) to Chromosome 16p13.3American Journal of Human Genetics, 2001
- Bone Resorption by OsteoclastsScience, 2000
- Direct Comparison of GeneChip and SAGE on the Quantitative Accuracy in Transcript Profiling AnalysisGenomics, 2000
- Synergetic activation of outwardly rectifying Cl− currents by hypotonic stress and external Ca2+ in murine osteoclastsThe Journal of Physiology, 1999
- Volume-activated Cl− channelsGeneral Pharmacology: The Vascular System, 1996
- Cortical bone remodeling in autosomal dominant osteopetrosis: A study of two different phenotypesBone, 1996
- ClC‐6 and ClC‐7 are two novel broadly expressed members of the CLC chloride channel familyFEBS Letters, 1995
- Chloride channels of intracellular organellesCurrent Opinion in Cell Biology, 1995
- Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.Journal of Clinical Investigation, 1994